Laddar...
Philadelphia-positive acute lymphoblastic leukemia patients already harbor BCR-ABL kinase domain mutations at low levels at the time of diagnosis
BACKGROUND: In patients with Philadelphia-positive acute lymphoblastic leukemia, resistance to treatment with tyrosine kinase inhibitors is frequent and most often associated with the development of point mutations in the BCR-ABL kinase domain. We aimed to assess: (i) in how many patients BCR-ABL ki...
Sparad:
| Huvudupphovsmän: | , , , , , , , , , , , , , , , , , , |
|---|---|
| Materialtyp: | Artigo |
| Språk: | Inglês |
| Publicerad: |
Ferrata Storti Foundation
2011
|
| Ämnen: | |
| Länkar: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3069232/ https://ncbi.nlm.nih.gov/pubmed/21193419 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2010.034173 |
| Taggar: |
Lägg till en tagg
Inga taggar, Lägg till första taggen!
|